



(51) International Patent Classification:

C07D 281/16 (2006.01) **A61P 25/18** (2006.01)
A61K 31/554 (2006.01) **A61P 25/24** (2006.01)

(21) International Application Number:

PCT/SE2009/050763

(22) International Filing Date:

18 June 2009 (18.06.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/074,417 20 June 2008 (20.06.2008) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) **Inventors/Applicants (for US only): BROWN, Dean** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **DAMEWOOD, James R.** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **EDWARDS, Phil** [US/US]; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **HULSIZER, James** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **MUIR, James Campbell** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **PIERSON JR., M. Edward** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **SHENVI, Ashokkumar Bhikkappa** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington,

Delaware 19850-5437 (US). **WESOLOWSKI, Steven** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **WIDZOWSKI, Dan** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **WOOD, Michael** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DIBENZOTHAIAZEPINE DERIVATIVES AND USE THEREOF



(57) **Abstract:** Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.